Determination of frequency of spontaneous resistance for gepotidacin and levofloxacin against a collection of gram-positive and gram-negative organisms
Abstract
Gepotidacin is a novel, bactericidal, first-in-class triazaacenaphthylene antimicrobial recently approved by the Food and Drug Administration (FDA) and Medicines and Healthcare products Regulatory Agency for the treatment of uncomplicated urinary tract infections (uUTI) and by the FDA for uncomplicated urogenital gonorrhea. Gepotidacin selectively inhibits type II topoisomerases involved in bacterial DNA replication by a distinct binding site and novel mechanism of action, conferring in vitro activity against most uropathogens, including those resistant to current antimicrobials. This study evaluated the potential of gepotidacin to select for spontaneous resistance in Citrobacter freundii, Enterobacter cloacae species complex, Klebsiella aerogenes, Klebsiella pneumoniae, Proteus mirabilis, Providencia rettgeri, Enterococcus faecalis, and Staphylococcus saprophyticus clinical isolates. Mutant frequencies ranged from 6.1 × 10-8 to <2.5 × 10-10 at 4× gepotidacin MIC concentrations, and no mutant isolates were recovered at 10× gepotidacin MIC concentrations. No target gene-specific (gyrA, gyrB, parC, parE) cross-resistance was observed with any of the comparators tested. As gepotidacin target site mutations in gyrA/B were only found in Enterococcus faecalis, repressor inactivation or activator dysregulation mutations in efflux pumps were identified as possible mechanisms of reduced susceptibility in the Gram-negative isolates. Further investigation is needed into the relevance…
Read the paper
Related studies
- Association of lower urinary tract symptoms and OAB severity with quality of life and mental health in China, Taiwan and South Korea: results from a cross-sectional, population-based study
- Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China
- The Role of the NLR and PLR in Urinary Tract Infection
- Threat of Antimicrobial Resistance among Pilgrims with Infectious Diseases during Hajj: Lessons Learnt from COVID-19 Pandemic
- Leclercia adecarboxylata urinary tract infection in a patient with bladder cancer and recurrent hematuria
- A Case Series of Staphylococcus lugdunensis Infection in Cancer Patients at an Academic Cancer Institute in the United States
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.